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Summary
Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of noso-
comial infections. Clinical presentation of infections is determined by the way of the 
acquisition of the pathogen then by virulence factors itself. In the intensive care units 
MRSA causes blood stream infections (BSI) associated with the use of venous lines 
as well as ventilator-associated pneumonia (VAP). MRSA is prone to form biofilm on 
implanted foreign materials like orthopaedic and other prostheses, catheters, artificial 
heart valves and cause persistent infections of surrounding tissues which are difficult to 
treat. It is difficult to eradicate infection without extraction of these materials. MRSA is 
weaker inductor of general inflammatory reaction then MSSA. Increase in patient’s mor-
tality and morbidity is associated more with a delay of appropriate antibiotic treatment 
then severity of infection. New antibiotics like linezolid, daptomycin, tygecycline, cefta-
rolin, ceftobiprol are available nowadays for the treatment of these infections. Although 
glycopeptides are still the first line treatment of MRSA infections, increase of minimal 
inhibitory concentrations (MIC creep) is associated with poorer outcome.
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Health - care associated methicillin-resistant Staphylococcus aureus (MRSA) in-
fections still represent an important threat for patients welfare all around the world 
[1]. Although recently a gradual decrease in the incidence of nosocomial MRSA 
infections is reported [2], new aspects in the epidemiology of MRSA infections 
showed that the burden of MRSA associated infections still exists and substantially 
increases patients’ morbidity and mortality. Two major factors are: 1) the increasing 
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number of outpatients with extensive healthcare contact, and 2) the emergence of 
community-acquired (CA) clones of methicillin-resistant staphylococci. Since the 
number of patients treated as outpatients increases, an increasing prevalence of he-
alth-care-associated (HCA) is reported [3]. CA infections has been registered both in 
the United States and Europe [4]. 
The objective of this review is to present the problem of HCA MRSA, since CA 
MRSA infections are still uncommon. The most common nosocomial-infections are 
primary blood-stream infections including endocarditis, associated with central ve-
nous catheters, artificial valves or intracardiac devices, pneumonia and postoperati-
ve infections like meningitis/ventriculitis or osteomyelitis. 
Primary blood stream infections
Central-venous-catheter (CVC) associated blood stream infections still repre-
sent a major threat to critically ill patients, but also for other patients who require 
a prolonged use of CVC like cancer or haematological patients. The incidence of 
MRSA infections is a significant indicator of a poorer infection control, since MRSA 
infections are generally exogenous infections spread on the hands of ICU personal. 
Coagulase-negative staphylococci are the most common pathogens associated with 
such infections, but MRSA still cause about 5 to 11% of these infections [5]. Insertion 
of CVC increases the risk of MRSA bacteraemia about 35 times [6]. MRSA bacterae-
mia significantly increases the risk of hospital death about three times, particular-
ly in elderly patients [7]. Two meta-analyses examined mortality associated with 
MSSA and MRSA infections. MRSA infection was associated with an increase in the 
risk of death, compared with MSSA infection in both analyses [8,9]. The reason was 
not MRSA infection per se but delay of appropriate therapy.
The risk of MRSA infections depends on insertion site. It is more common with 
femoral or jugular CVC than subclavian pathway [10]. The incidence of MRSA 
CVC associated bacteraemia is significantly reduced in countries where rigorous 
preventive measures had been applied.
MRSA is the major pathogen associated with health-care associated endocar-
ditis which represents a growing problem due to the greater number of invasive 
procedures applied in patients burdened with serious comorbidities [11]. This is the 
biggest study regarding staphylococcal infective endocarditis (IE). Most patients 
with health care−associated S. aureus IE (131 patients, 60.1%) acquired the infection 
outside of the hospital. MRSA IE was more common in the United States (37.2%) 
and Brazil (37.5%) than in Europe/Middle East (23.7%) and Australia/ New Zealand 
(15.5%). Interestingly, haemodialysis was a very common exposure preceding endo-
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carditis. Comparison of MRSA and MSSA infections showed that persistent bacte-
raemia was more common in patients with MRSA IE (42.6% vs. 8.8%), but there was 
no difference in in-hospital mortality (29.8% vs.23.3%). An Australian study showed 
that a higher number of patients with MRSA IE was subdued to cardiac surgery 
(59%) but the mortality remained very high (66%) [12]. During the last decade the 
number of patients with cardiac intraventricular devices increased. Most intravas-
cular device infections are thought to result from skin flora contamination during 
implantation [13]. Infection of the subcutaneous portion of the device can subsequ-
ently track to deeper intravascular tissues. Infection that involves the intravascu-
lar or intracardiac portion of these devices carries a high morbidity and mortality. 
Despite appropriate antibiotic therapy, cure of infection is frequently possible only 
with device removal. MRSA might be a significant pathogen associated with these 
infections although coagulase-negative staphylococci prevail.
Ventilator-associated Pneumonia
MRSA is an important pathogen associated with the development of VAP. The 
epidemiology of MRSA pneumonia varies across countries. Methicillin resistance in 
S. aureus ventilator associated pneumonia (VAP) ranged between 37 % in German, 
54 % in the US American and 78 % in Asian and Latin American ICUs [14]. Cru-
de hospital mortality in studies performed after 2005 varies between 27 % and 59 
% and attributable MRSA pneumonia mortality at 40%. Diagnosis of VAP requires 
beside x-ray of the chest a prompt microbiological diagnosis (Gram staining of the 
appropriate respiratory specimen, determination of the number of colony-forming 
units per millilitre, and permanent and prompt contact with clinicians). Close coo-
peration between microbiologist and clinician results in better timing of appropri-
ate therapy which further improves patients’ outcome. Risk factors associated with 
MRSA VAP were older age, medical patients, more comorbidities. Consequences 
were prolonged hospitalization and significantly increased cost [15]. 
PostoPeratiVe infections
meningitis
MRSA is an important pathogen associated with postoperative and shunt- me-
ningitis. S.aureus is cause of shunt meningitis in about one third of patients. Beside 
presence of fever and signs of meningitis, shunt infections may result in peritonitis 
in patients with ventriculoperitoneal shunts or right-sided endocarditis in ventricu-
loatrial shunts. Usually infections are slowly progressing [16]. Removal of the shunt 
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is necessary for eradication of infection. Existing shunt is replaced with external 
ventricular drainage, and intensively treated. After resolving of meningitis, perma-
nent shunt is implanted again.
osteomyelitis
Osteomyelitis after surgical interventions is usually caused by coagulase-nega-
tive staphylococci. All bones may be affected. There is no large epidemiologic study 
to estimate the true incidence of MRSA osteomyelitis among postoperative patients. 
Rather, small case-series are presented. Prolonged antibiotic use is mandatory in 
these patients, often with combined antibiotic regimens since replacement of artifi-
cial materials is often impossible.
treatment
Early appropriate antibiotic therapy is the cornerstone of successful therapy and 
positive patients’ outcome. Early studies showed that mortality directly related to 
pneumonia was significantly higher among patients with MRSA episodes (RR = 
20.72, 95% CI = 2.78-154.35) [17]. Subsequent studies showed that a delay in appro-
priate treatment was the major contributing factor of a poor outcome. more than 
MRSA infection per se, particularly after adjustments for other contributing factors. 
However, only a half of patients with MRSA bacteraemia received an appropriate 
empirical therapy [18]. In a study of Zahar et al. the crude hospital mortality rate 
was higher for MRSA-infected patients than for MSSA-infected patients (59.4% vs. 
40%; P = .024), but this difference disappeared after controlling for time in the ICU 
before VAP and parameters imbalanced at ICU admission (odds ratio [OR], 1.23; 
95% confidence interval [CI], 0.49-3.12; P = .7) and remained unchanged after further 
adjustments for initial treatment adequacy and polymicrobial VAP (OR, 0.98; 95% 
CI, 0.36-2.66) [19]. Appropriate empirical antibiotic treatment has also a significant 
survival benefit in MRSA bacteraemia. Pooling of six studies using adequate met-
hodology for the adjusted analysis resulted in an OR of 1.98 (95% CI 1.62-2.44) for a 
delay of appropriate therapy [20]. These data suggest that early diagnosis of MRSA 
infection and wide-spectrum therapy with subsequent de-escalation in settings 
where MRSA infections are common are mandatory [21].
MRSA infections are still difficult-to-treat infections. For many years glycopep-
tides (vancomycin or teicoplanin) were the antibiotics of choice in the treatment of 
MRSA infections. Even today they are still first line therapy due to their safety and 
acceptable costs. However, since these agents have large molecules, accumulation 
in tissues, penetration of blood-brain barrier might represent a problem [22]. That is 
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why a need for other potent antibiotics led companies to develop many other drugs. 
Another potential problem in the treatment of MRSA infections is a phenomena of 
creeping (increase in the MIC values but still within sensitivity limits) vancomycin 
minimal inhibitory concentration (MIC) values which resulted with more treatment 
failures of glycopeptide therapy. That is why it seems prudent to treat infections 
caused by MRSA strains with MIC values above 1 mg/L with other antibiotics – dap-
tomycin for blood-stream infections and endocarditis and linezolid for pneumonia. 
However, all studies did not uniformly support negative impact of raised MICs on 
outcome.
Currently, vancomycin remains the gold-standard treatment option for MRSA 
infections. In situations that limit its use, consideration of patient-specific parame-
ters, cost, and relevant clinical data demonstrating drug safety and efficacy should 
be employed for the selection of the appropriate alternative agent [23].
Antibiotics presently used in the treatment of MRSA infections are presented 
on Table 2.
MRSA infections are world-wide still an important cause of health-care associ-
ated infections. They spilled over into community and there is a growing number 
of patients admitted into hospitals with MRSA infections not acquired during the 
health-care process. Effective preventive measures decrease but do not eliminate 
MRSA infections. CA-MRSA infections caused by particular MRSA strains are not 
in Croatia as common as in USA but a constant alert is necessary to recognize ou-
tbreak of these infection.
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Sažetak
Spektar infekcija uzrokovanih meticilin-rezistentnim sojevima Staphylococcus aureus
Infekcije MRSA-om važan su uzročnik bolničkih infekcija. Spektar bolesti koje MRSA izaziva 
određen je više načinom akvizicije tijekom raznih oblika medicinske skrbi nego patogenetskim 
značajkama samog organizma. Invazivni zahvati nose rizik infekcija MRSA-om. Glavni su način 
širenja ruke osoblja, pa su infekcije MRSA-om pokazatelj egzogenog akviriranja bolničke infek-
cije. Na kirurškim odjelima važan su uzročnik infekcija rana, tkiva i mekih česti. U jedinicama 
intenzivne medicine uzročnik su infekcija krvotoka povezanih s primjenom centralnih venskih 
katetera i pneumonija povezanih s provođenjem strojnog disanja, odnosno intubacije. Infekcije 
MRSA-om velik su problem kod ugradnje stranih materijala jer, zbog stvaranja biofilma, lako 
koloniziraju proteze, drenažne katetere ili umjetne zalistke te uzrokuju perzistentne infekcije 
okolnog tkiva koje je vrlo teško liječiti. Zbog toga je potrebno zamijeniti te materijale, što nije 
laka odluka niti je to uvijek moguće učiniti. Za razliku od infekcija MSSA-om, infekcije MRSA-om 
povezane su sa slabijom indukcijom opće upalne reakcije. Iako su povezane sa znatnim poveća-
njem morbiditeta i smrtnosti, ove posljedice infekcija MRSA-om više su posljedica neprepozna-
vanja ili kašnjenja ispravnog antibiotskog liječenja nego težine infekcije. Danas na raspolaganju 
imamo čitav spektar novijih antibiotika (linezolid, daptomicin, tigeciklin, ceftarolin, ceftobiprol) 
kojima se, uz glikopeptide, možemo uspješno suprotstaviti infekcijama MRSA-om, ali rastući je 
problem smanjenje osjetljivosti na vankomicin, što ima bitne kliničke posljedice.
Ključne riječi: MRSA; spektar infekcija
